275 related articles for article (PubMed ID: 28100839)
21. Agents that bind annexin A2 suppress ocular neovascularization.
Lima e Silva R; Shen J; Gong YY; Seidel CP; Hackett SF; Kesavan K; Jacoby DB; Campochiaro PA
J Cell Physiol; 2010 Nov; 225(3):855-64. PubMed ID: 20607799
[TBL] [Abstract][Full Text] [Related]
22. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
Saishin Y; Saishin Y; Takahashi K; Lima e Silva R; Hylton D; Rudge JS; Wiegand SJ; Campochiaro PA
J Cell Physiol; 2003 May; 195(2):241-8. PubMed ID: 12652651
[TBL] [Abstract][Full Text] [Related]
23. JP1, a polypeptide specifically targeting integrin αVβ3, ameliorates choroidal neovascularization and diabetic retinopathy in mice.
Xie Z; Wu XJ; Cheng RW; Cui JH; Yuan ST; Zhou JW; Liu QH
Acta Pharmacol Sin; 2023 Apr; 44(4):897-912. PubMed ID: 36280689
[TBL] [Abstract][Full Text] [Related]
24. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
25. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
[TBL] [Abstract][Full Text] [Related]
27. [Not Available].
García Layana A; Donate López J
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():1-2. PubMed ID: 25925043
[No Abstract] [Full Text] [Related]
28. Aflibercept for the treatment of diabetic macular edema.
Harkins KA; Haschke M; Do DV
Immunotherapy; 2016 May; 8(5):503-10. PubMed ID: 26907516
[TBL] [Abstract][Full Text] [Related]
29. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM; Neiweem AE; Kansara V; Harris A; Ciulla TA
Expert Opin Investig Drugs; 2019 Oct; 28(10):861-869. PubMed ID: 31513439
[No Abstract] [Full Text] [Related]
30. [New perspectives in the approach to age-related macular degeneration].
Gallego-Pinazo R; Zapata MA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():11-4. PubMed ID: 25925046
[TBL] [Abstract][Full Text] [Related]
31. AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.
Liu Y; Fortmann SD; Shen J; Wielechowski E; Tretiakova A; Yoo S; Kozarsky K; Wang J; Wilson JM; Campochiaro PA
Mol Ther; 2018 Feb; 26(2):542-549. PubMed ID: 29292162
[TBL] [Abstract][Full Text] [Related]
32. Oxidative stress promotes ocular neovascularization.
Dong A; Xie B; Shen J; Yoshida T; Yokoi K; Hackett SF; Campochiaro PA
J Cell Physiol; 2009 Jun; 219(3):544-52. PubMed ID: 19142872
[TBL] [Abstract][Full Text] [Related]
33. TYPE 2 (SUBRETINAL) NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH PURE RETICULAR PSEUDODRUSEN PHENOTYPE.
Naysan J; Jung JJ; Dansingani KK; Balaratnasingam C; Freund KB
Retina; 2016 Mar; 36(3):449-57. PubMed ID: 26383711
[TBL] [Abstract][Full Text] [Related]
34. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
35. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.
Takahashi K; Saishin Y; Saishin Y; Silva RL; Oshima Y; Oshima S; Melia M; Paszkiet B; Zerby D; Kadan MJ; Liau G; Kaleko M; Connelly S; Luo T; Campochiaro PA
FASEB J; 2003 May; 17(8):896-8. PubMed ID: 12670875
[TBL] [Abstract][Full Text] [Related]
36. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.
Miki K; Miki A; Matsuoka M; Muramatsu D; Hackett SF; Campochiaro PA
Ophthalmology; 2009 Sep; 116(9):1748-54. PubMed ID: 19643496
[TBL] [Abstract][Full Text] [Related]
37. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
38. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness.
Sariyeva Ismayılov A; Esen E; Sızmaz S; Demircan AN
Clin Exp Optom; 2019 Nov; 102(6):617-620. PubMed ID: 30793798
[TBL] [Abstract][Full Text] [Related]
39. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
[TBL] [Abstract][Full Text] [Related]
40. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells.
Miki A; Miki K; Ueno S; Wersinger DM; Berlinicke C; Shaw GC; Usui S; Wang Y; Zack DJ; Campochiaro PA
J Cell Physiol; 2010 Jul; 224(1):262-72. PubMed ID: 20232317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
